{"id":6167,"date":"2025-03-27T13:45:13","date_gmt":"2025-03-27T10:45:13","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6167"},"modified":"2025-03-27T13:45:13","modified_gmt":"2025-03-27T10:45:13","slug":"the-swedeheart","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-swedeheart\/","title":{"rendered":"the SWEDEHEART"},"content":{"rendered":"
Intensive early and sustained lowering of non\u2013high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry:<\/div>\n
<\/div>\n
Summary of the Study on Atherogenic Lipoproteins and Non\u2013HDL-C in MI Patients.<\/div>\n
<\/div>\n
Highlighted by ESC.<\/div>\n
\u00a02024, European Heart Journal.<\/div>\n
<\/div>\n
1. Atherogenic Lipoproteins & Non\u2013HDL-C<\/span><\/div>\n
\u2022 Atherogenic lipoproteins include LDL, lipoprotein(a), and triglyceride-rich remnants.<\/span><\/div>\n
\u2022 All contain a single apolipoprotein B (apoB) molecule and contribute to atherosclerosis risk.<\/span><\/div>\n
\u2022 Non\u2013HDL-C is a consolidated metric estimating atherogenic cholesterol content.<\/span><\/div>\n
\u2022 Non\u2013HDL-C is mostly comprised of LDL-C but better reflects total lipid risk, especially in high triglyceride states(Non\u2013HDL-C includes all lipoproteins carrying apolipoprotein B (apoB), with the majority being LDL-C. However, unlike LDL-C, Non\u2013HDL-C provides a more comprehensive estimate of lipid-associated cardiovascular risk, especially in cases of hypertriglyceridemia. When triglyceride levels are high, LDL-C alone may underestimate the lipid risk, as it does not account for other atherogenic particles like VLDL and their remnants. Non\u2013HDL-C, on the other hand, reflects the total atherogenic lipid burden, including those additional lipid fractions, offering a better indicator of overall cardiovascular risk in these conditions).<\/span><\/div>\n
2. Lipid-Lowering Therapies<\/span><\/div>\n
\u2022 Statins and other therapies lower LDL-C, non\u2013HDL-C, and apoB by increasing LDL receptor activity.<\/span><\/div>\n
\u2022 High-intensity statins post-MI reduce cardiovascular events more effectively than moderate-intensity statins.<\/span><\/div>\n
\u2022 Adding ezetimibe to statins further improves outcomes.<\/span><\/div>\n
\u2022 PCSK9 inhibitors offer additional benefits when LDL-C remains uncontrolled post-MI.<\/span><\/div>\n
3. Study Design & Population<\/span><\/div>\n
\u2022 Used data from the SWEDEHEART registry, covering MI patients in Sweden.<\/span><\/div>\n
\u2022 Included 18\u201379-year-old patients with first-time MI (2005\u20132022), without prior atherosclerotic disease.<\/span><\/div>\n
\u2022 Follow-up at 2 months and 1 year via cardiac rehabilitation programs.<\/span><\/div>\n
\u2022 Patients needed non\u2013HDL-C measurements at admission and at follow-ups.<\/span><\/div>\n
4. Outcome Measures<\/span><\/div>\n
\u2022 Major adverse cardiovascular events (MACE): all-cause mortality, non-fatal MI, or non-fatal stroke.<\/span><\/div>\n
\u2022 Follow-up continued until death or April 2022.<\/span><\/div>\n
\u2022 Early (2-month) non\u2013HDL-C levels were assessed for short-term and long-term impact.<\/span><\/div>\n
5. Key Findings<\/span><\/div>\n
\u2022 Achieving non\u2013HDL-C target (<2.2 mmol\/L) early (within 2 months) and sustaining it resulted in the best outcomes.<\/span><\/div>\n
\u2022 Delayed lipid target achievement, as seen in the stepwise therapy approach, may lead to avoidable harm.<\/span><\/div>\n
\u2022 Findings suggest an urgent need to revise current lipid-lowering strategies post-MI.<\/span><\/div>\n
<\/div>\n
https:\/\/doi.org\/10.1093\/eurheartj\/ehae576<\/div>\n","protected":false},"excerpt":{"rendered":"

Intensive early and sustained lowering of non\u2013high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry: Summary of the Study on Atherogenic Lipoproteins and Non\u2013HDL-C in MI Patients. Highlighted by ESC. \u00a02024, European Heart Journal. 1. Atherogenic Lipoproteins & Non\u2013HDL-C \u2022 Atherogenic lipoproteins include LDL, lipoprotein(a), and triglyceride-rich remnants. \u2022 All contain a single […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6167","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6167"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6167\/revisions"}],"predecessor-version":[{"id":6168,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6167\/revisions\/6168"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}